Literature DB >> 30496455

Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs.

Tawanda Gumbo1, Jan-Willem C Alffenaar2.   

Abstract

A World Health Organization workshop systematically examined the evidence base for dosing second-line tuberculosis drugs, identifying knowledge gaps. To fill these in, pharmacokinetics/pharmacodynamics, Monte Carlo experiments, and artificial intelligence algorithms were used in hollow-fiber model studies and clinical data analyses.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30496455      PMCID： PMC6260166          DOI： 10.1093/cid/ciy608

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  44 in total

1.  Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.

Authors:  Jotam G Pasipanodya; Shashikant Srivastava; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2012-03-30       Impact factor: 9.079

2.  Serum drug concentrations predictive of pulmonary tuberculosis outcomes.

Authors:  Jotam G Pasipanodya; Helen McIlleron; André Burger; Peter A Wash; Peter Smith; Tawanda Gumbo
Journal:  J Infect Dis       Date:  2013-07-29       Impact factor: 5.226

3.  Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Radha K Shandil; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharath; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

4.  Population pharmacokinetics of micafungin in adult patients.

Authors:  Tawanda Gumbo; John Hiemenz; Lei Ma; James J Keirns; Donald N Buell; George L Drusano
Journal:  Diagn Microbiol Infect Dis       Date:  2007-11-19       Impact factor: 2.803

5.  Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin.

Authors:  Tawanda Gumbo; Arnold Louie; Mark R Deziel; Weiguo Liu; Linda M Parsons; Max Salfinger; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

6.  Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis.

Authors:  G L Drusano; D E Johnson; M Rosen; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

7.  Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharat; R K Shandil; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

8.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.

Authors:  A Forrest; D E Nix; C H Ballow; T F Goss; M C Birmingham; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

9.  Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis.

Authors:  Devyani Deshpande; Shashikant Srivastava; Paula Bendet; Katherine R Martin; Kayle N Cirrincione; Pooi S Lee; Jotam G Pasipanodya; Keertan Dheda; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

10.  Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients.

Authors:  Chawangwa Modongo; Jotam G Pasipanodya; Beki T Magazi; Shashikant Srivastava; Nicola M Zetola; Scott M Williams; Giorgio Sirugo; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191
View more
  5 in total

1.  Higher Dosing of Rifamycins Does Not Increase Activity against Mycobacterium tuberculosis in the Hollow-Fiber Infection Model.

Authors:  E D Pieterman; S van den Berg; A van der Meijden; E M Svensson; H I Bax; J E M de Steenwinkel
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

Review 2.  Quantitative assessment of the activity of antituberculosis drugs and regimens.

Authors:  Maxwell T Chirehwa; Gustavo E Velásquez; Tawanda Gumbo; Helen McIlleron
Journal:  Expert Rev Anti Infect Ther       Date:  2019-05-30       Impact factor: 5.091

3.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

4.  Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis.

Authors:  Jan-Willem C Alffenaar; Tawanda Gumbo; Kelly E Dooley; Charles A Peloquin; Helen Mcilleron; Andre Zagorski; Daniela M Cirillo; Scott K Heysell; Denise Rossato Silva; Giovanni Battista Migliori
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

Review 5.  Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs.

Authors:  Marieke G G Sturkenboom; Anne-Grete Märtson; Elin M Svensson; Derek J Sloan; Kelly E Dooley; Simone H J van den Elsen; Paolo Denti; Charles A Peloquin; Rob E Aarnoutse; Jan-Willem C Alffenaar
Journal:  Clin Pharmacokinet       Date:  2021-03-06       Impact factor: 6.447
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.